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Cervical cancer is a leading cause of cancer death among women in low-income countries, with B25% of cases worldwide occurring
in India. We estimated the potential health and economic impact of different cervical cancer prevention strategies. After empirically
calibrating a cervical cancer model to country-specific epidemiologic data, we projected cancer incidence, life expectancy, and lifetime
costs (I$2005), and calculated incremental cost-effectiveness ratios (I$/YLS) for the following strategies: pre-adolescent vaccination of
girls before age 12, screening of women over age 30, and combined vaccination and screening. Screening differed by test (cytology,
visual inspection, HPV DNA testing), number of clinical visits (1, 2 or 3), frequency (1 ,2  ,3   per lifetime), and age range
(35–45). Vaccine efficacy, coverage, and costs were varied in sensitivity analyses. Assuming 70% coverage, mean reduction in lifetime
cancer risk was 44% (range, 28–57%) with HPV 16,18 vaccination alone, and 21–33% with screening three times per lifetime.
Combining vaccination and screening three times per lifetime provided a mean reduction of 56% (vaccination plus 3-visit
conventional cytology) to 63% (vaccination plus 2-visit HPV DNA testing). At a cost per vaccinated girl of I$10 (per dose cost of $2),
pre-adolescent vaccination followed by screening three times per lifetime using either VIA or HPV DNA testing, would be considered
cost-effective using the country’s per capita gross domestic product (I$3452) as a threshold. In India, if high coverage of pre-
adolescent girls with a low-cost HPV vaccine that provides long-term protection is achievable, vaccination followed by screening
three times per lifetime is expected to reduce cancer deaths by half, and be cost-effective.
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More than 25% of cervical cancer cases worldwide occur in India
(Ferlay et al, 2004). Although cervical cancer is the most frequent
cancer diagnosis in Indian women, age-adjusted incidence rates
vary between regions, ranging from 10.9 in Trivandrum to 47.2 per
100000 person-years at risk in Chennai (Parkin et al, 2005).
Persistent infection with high risk types of human papilloma-
virus (HPV) is established as the key causal agent for cervical
cancer (IARC, 2005). In India, overall HPV prevalence in women
with normal cytology has been estimated to be 7.5% (de Sanjose ´
et al, 2007). Similar to cancer incidence, region-specific prevalence
of HPV varies considerably (Sankaranarayanan et al, 2004;
Franceschi et al, 2005; Laikangbam et al, 2007), likely attributable
to genetic and cultural diversity, as well as heterogeneity between
studies (Basu et al, 2003; Duttagupta et al, 2004).
New options for cervical cancer prevention motivate important
questions in low-income countries. Traditional cytology screening,
conducted at frequent intervals and requiring multiple clinic visits
for women with abnormal cytology (e.g., screening, diagnostic
testing, and treatment), has been difficult to implement in India
(Sankaranarayanan et al, 2001). Screening with HPV DNA testing
and/or visual inspection with acetic acid (VIA) have been
demonstrated to be acceptable and promising alternatives when
embedded in a screening protocol that requires fewer visits (Bhatla
et al, 2007; Ramachandran et al, 2007) and utilises cryotherapy
conducted by nurses to treat the majority of early cancer
precursors (Sankaranarayanan et al, 2001, 2006, 2007a,b). These
strategies, less dependent on existing health system infrastructure
and associated with greater rates of follow-up, are also expected to
be cost-effective (Goldie et al, 2005).
Most recently, two new vaccines have been shown to be highly
effective in preventing infection with HPV 16 and 18 in women
without prior exposure to these types (FDA, 2006). Contemplating
an HPV vaccination programme adds complexity to decision-
making about India’s national approach to cervical cancer control.
The country will want to consider the burden of cervical cancer,
the comparative effectiveness – and potential synergies – of
vaccination and screening, the financial costs required to initiate
and sustain programs, their cost-effectiveness, and the program-
matic capacity and infrastructure necessary to effectively deliver a
three-dose pre-adolescent vaccine. Although a single study would Revised 9 May 2008; accepted 12 May 2008; published online 8 July 2008
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sbe unable to include all of these factors, decision-analytic models
can be used to synthesise the best available epidemiologic, clinical
and economic data, and project long-term health and economic
outcomes expected with different cancer prevention strategies. To
provide insight to decision makers and stakeholders invested in
reducing mortality from cervical cancer in India, we assessed the
potential avertable burden of disease and cost-effectiveness
associated with various vaccination and screening strategies.
MATERIALS AND METHODS
Analytic overview
A previously described computer-based model of cervical carci-
nogenesis (Goldie et al, 2007; Kim et al, 2007a) was calibrated to
epidemiologic data in India and used to compare the health
(cancer incidence reduction, life expectancy gains) and economic
(discounted lifetime costs) impact of the following strategies: (1)
HPV 16,18 vaccination of girls below age 12 (herein referred to as
pre-adolescent vaccination), (2) screening of adult women over age
30 using HPV DNA testing, cervical cytology, or VIA, and (3)
combined vaccination and screening. We followed published
recommendations for economic evaluations (DCPP; Gold et al,
1996; Drummond et al, 2005; WHO CHOICE) by adopting a
societal perspective and discounting future costs and life years by
3% annually. Performance of alternative strategies was measured
using incremental cost-effectiveness ratios, defined as the addi-
tional cost of a specific strategy (in 2005 international dollars, I$),
divided by its additional benefit (per woman life expectancy gain),
compared with the next most costly strategy. Parameter un-
certainty was evaluated using one- and two-way sensitivity
analysis, and probabilistic analysis.
Model
The individual-based stochastic model has been previously
described (Goldie et al, 2007; Kim et al, 2007a), with the natural
history of cervical cancer represented as a sequence of monthly
transitions between mutually exclusive health states. Individual
girls representative of a single birth cohort enter the model at age
9, before sexual debut, and are followed throughout their lifetimes.
Transitions between health states depend on HPV type, age, and
history of prior type-specific infection (i.e., natural immunity).
Human papillomavirus types were categorized as follows: (1) high-
risk type 16 (HR 16); (2) high-risk type 18 (HR 18); (3) other high-
risk types (HR other) (HR types: 26, 31, 33, 35, 39, 45, 51, 52, 53,
56, 58, 59, 66, 68, 73, and 82 (IS39 and MM4 subtypes)), and (4)
low-risk types (LR) (LR types: 6, 11, 30, 32, 34, 40, 42, 43, 44, 54, 55,
57, 61, 64, 67, 69, 70, 71 (CP8061), 72, 81 (CP8304), 83 (MM7), and
84 (MM8), cand85, 86, cand89 (CP6108) and JC9710) (Mun ˜oz et al,
2003). Women with infection with high-risk types and high-grade
cervical disease may progress to invasive cancer, and may then be
detected through symptoms or screening, be diagnosed and
treated, or progress to the next stage of cancer. Women with
cancer face stage-specific survival rates, although all women face
all-cause age-specific competing mortality risks.
Epidemiological data
We assumed that the mechanism of cervical carcinogenesis does
not fundamentally differ between countries; as such, initial natural
history model estimates, and their plausible ranges, were based on
the best available data regardless of specific setting. However, as
epidemiology (e.g., HPV type distribution), risk factors (e.g., age at
sexual debut, number of sexual partners), and age-specific cervical
cancer rates differ between regions, we then calibrated the model
to country-specific data. We capitalised on the availability of data
from southeastern India for nearly all epidemiological targets
required for our calibration procedure. Age-specific and type-
specific prevalence of HPV in women with normal cytology and
age-specific prevalence and type distribution of cervical intra-
epithelial neoplastia (CIN) lesions were derived from the IARC
survey in the Tamil Nadu state (Franceschi et al, 2005); HPV type
distribution in cervical cancer was extracted from a case–control
study in the same state (Franceschi et al, 2003). Cancer incidence
data were drawn from two population-based cancer registries from
southern India, Bangalore (Karnataka) and Chennai (Tamil Nadu),
reported in the Cancer Incidence in Five Continents (CI5C)
(Parkin et al, 2005).
Details of the model parameterisation process can be found in the
Supplementary Appendix and previous publications (Goldhaber-
Fiebert et al, 2007; Goldie et al, 2007; Kim et al, 2007a). Briefly,
after initial values and plausible ranges for each model input
parameter were established, repeated simulations were under-
taken, each drawing different combinations of parameter values
and projecting model outcomes with each set of parameter
combinations. The outcomes produced by each parameter set
were scored according to their fit with multiple calibration target
data based on likelihood scoring functions. A composite goodness-
of-fit score for each parameter set was computed by summing the
log likelihood of each model outcome. Figure 1 shows examples of
model output from a sample of a good-fitting parameter sets
compared with the empirical data. Additional results may be found
in the Supplementary Appendix.
To explicitly incorporate the effect of parameter uncertainty,
cost-effectiveness analyses were conducted with a random sample
of good-fitting parameter sets, and results were reported as the
mean and range of outcomes, whereas incremental cost-effective-
ness ratios were reported as the ratio of the mean costs divided by
the mean effects of one strategy vs another across the good-fitting
parameter sets (Stinnett and Paltiel, 1997).
Strategies
Vaccination occurs before sexual debut (before age 12) and may or
may not be combined with screening. In the base case analysis, we
elected to assume 70% of the birth cohort was successfully
vaccinated with three doses; in doing so, we aimed to (i) establish
an estimate for the avertable burden of disease with optimal
delivery and implementation of the intervention without making
assumptions about the differential operational capacity to deliver
the vaccine, and (ii) allow for comparison with other cost-
effectiveness analyses in the literature. We also assumed vacci-
nated girls have life-long protection against HPV 16 and 18, but are
subject to the same rate of infection with other high-risk HPV
types as those who are not vaccinated. We explored the
implications of waning immunity and different levels of coverage
(10–90%) and vaccine efficacy (50–100%).
Screening strategies differ by the initial screening test (cervical
cytology, VIA, HPV DNA testing), screening frequency (once,
twice, three times per lifetime), target ages (35, 40, and 45), and the
number of clinical visits (1, 2 or 3) required for women to be
screened, be informed of results, and receive any necessary
treatment. In the base case, we assumed 70% screening coverage
starting at age 35 with subsequent screens occurring at 5-year
intervals. In the three-visit cytology strategy, women are screened
in the first visit, and those who are screen-positive undergo
colposcopy/biopsy in a second visit, followed by treatment of
abnormalities at a district or tertiary clinical care site in a third
visit. Treatment for precancerous lesions or cancer depends on
lesion size and type (e.g., cryosurgery, loop electrosurgical excision
procedure, cold knife conisation, or simple hysterectomy). In the
two-visit HPV DNA testing strategy, women are screened in the
first visit, return for results in a second visit, and screen-positive
women who are eligible for cryosurgery are treated on the same
day; those who are not (e.g., lesions covering over 75% of the
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scervix or extending to the vaginal wall) are referred to a secondary
facility for further diagnostic testing and, potentially, treatment.
Loss to follow-up between each visit is assumed to be 15%. One-
visit strategies (VIA and rapid HPV DNA testing) incorporate
same-day screening and treatment for women with positive
screening results.
Cost data
Selected cost estimates were based on data from a previously
published analysis of screening in India (Goldie et al, 2005)
(Table 1 and Supplementary Appendix). Costs from Goldie et al
(2005), which were in I$2000 international dollars (I$), were
converted to I$2005 using Purchasing Power Parity (PPP)
conversion rates and the gross domestic product (GDP) implicit
price deflator (World Bank). Since the HPV vaccine price and the
programmatic costs to deliver a pre-adolescent vaccine in India are
not yet known, we expressed a composite value, the ‘cost per
vaccinated girl’, and varied it from I$5 to I$360. For example, for
a composite cost of I$10 per vaccinated girl, we assumed three
doses of vaccine at $2.00 each; wastage of $0.90; freight
and supplies of $0.59; administration of I$0.50; and immunisation
support and programmatic costs of I$2.00. All costs were
expressed in I$2005.
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Figure 1 Model calibration. Selected model output from a random sample of good-fitting parameter sets are compared with the 95% confidence intervals
of the empirical data (solid black lines) including HPV type distribution in cervical disease (upper panel) and age-specific cancer incidence rates (lower panel).
Additional calibration results can be found in the Supplementary Appendix.
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sRESULTS
Reduction in lifetime risk of cancer
Pre-adolescent vaccination alone reduced cancer incidence by 44%
(range, 28–57%) and was more effective than screening alone
(Figure 2, upper panel). A combined approach of pre-adolescent
vaccination and screening of adult women was more effective than
either alone (Figure 2, lower panel). The relative differences
between individual testing strategies were attenuated in the
presence of widespread vaccination.
Cost-effectiveness of vaccination and screening
Table 2 displays the cost-effectiveness results (cost per year of life
saved (YLS)), as the cost per vaccinated girl is varied. In addition
to conducting analyses that assumed all screening tests would be
equally available (Table 2a), we performed analyses that assumed
only HPV DNA testing was available (Table 2b). Although there is
no consensus on a specific cost-effectiveness threshold, below
which an intervention would be considered cost-effective, one
suggested heuristic has been to use the country’s per capita GDP
(WHO, 2001). Although realistically the threshold ratio may need
to be much lower for the intervention to be affordable, we
considered strategies that had cost-effectiveness ratios lower
than the per capita GDP in India (I$3452) (World Bank) to be
cost-effective.
All strategies equally available Assuming that all strategies
were equally available (Table 2a) and provided the cost per
vaccinated girl was I$10 ($2 per dose) or less, vaccination alone
was more effective and cost-effective than screening alone.
Vaccination and screening three times per lifetime with VIA was
I$290 per YLS. When the cost per vaccinated girl reached and
exceeded I$20, screening three times per lifetime (at ages 35, 40,
and 45) with a single-visit VIA strategy was less costly and more
cost-effective than vaccination alone, and cost I$60 per YLS
compared to no intervention. At a vaccine price per dose of
approximately $100 (I$360 per vaccinated girl), vaccination was
dominated by (i.e., either less costly and less cost-effective than
or more costly and less effective than) screening alone. The
cost-effectiveness ratio for a combined vaccination and screen-
ing strategy with single-visit VIA increased from I$290 per YLS
at I$10 per vaccinated girl to I$7230 per YLS at I$360 per
vaccinated girl.
Only HPV DNA testing available In some settings, reliable VIA
screening and treatment in a single visit may not be feasible. If
only HPV DNA testing was available (Table 2b), provided the cost
per vaccinated girl was below I$50, screening alone was
dominated. Vaccination alone ranged from cost saving at I$10
per vaccinated girl ($2 per dose) to I$890 per YLS at I$50 per
vaccinated girl. Across this same range of vaccine costs, pre-
adolescent vaccination combined with two-visit HPV DNA testing
three times per lifetime was I$1780 per YLS; at higher costs (I$360
per vaccinated girl) this strategy increased to I$7650 per YLS,
compared to the next best strategy.
Once the cost per vaccinated girl reached I$50, screening alone
was no longer dominated. In this case, screening three times per
lifetime with two-visit HPV DNA testing was I$720 per YLS,
compared to no intervention. At a cost per vaccinated girl of I$75
and above, vaccination alone was no longer cost-effective.
Sensitivity analysis
Assuming a cost of I$20 per vaccinated girl, if VIA screening was
30% less sensitive and costs were increased to I$2, vaccination
alone dominated VIA screening, although VIA combined with
vaccination approximated I$975 per YLS (see Supplementary
Appendix).
The choice between specific screening modalities was sensitive
to assumptions about their relative costs, test performance, and
ability to be delivered within one or two visits. For example, if
training costs associated with VIA raised the total screening cost
such that it would approach that of HPV DNA testing, vaccination
plus screening three times per lifetime with two-visit HPV DNA
testing was favored, at I$1780 per YLS – if a rapid HPV DNA test
was available, allowing for a single-visit screen-and-treat strategy,
this result would become even more favourable. All strategies
Table 1 Selected cost variables
a
Variable Base case
Vaccine costs
b
Cost per vaccinated individual 50.00
Vaccine cost (three doses   unit cost) 36.74
Vaccine wastage 5.51
Freight, supplies, supply wastage, and administration 2.81
Monitoring and programmatic services 2.94
Cold chain, injection safety, operational costs 2.00
Screening, diagnostic, and treatment costs
c,d
HPV DNA test 10.30
Cytology 3.69
Visual inspection with acetic acid 1.25
Colposcopy and biopsy 40.30
Cryotherapy 16.00
Loop electrosurgical excision procedure 106.99
Cold knife conisation 237.02
Simple hysterectomy 338.59
Invasive cervical cancer costs
e
Local 1611.57
Regional/distant 2346.94
Patient time and transportation costs
f
Patient average hourly wage 0.30
Screening visit 0.74
Diagnostic visit 15.44
Cryotherapy visit 0.76
Loop electrosurgical excision procedure visit 15.49
Cold knife conisation visit 24.57
Simple hysterectomy visit 37.29
aCosts reported in I$2005, a currency that provides a means of translating and
comparing costs among countries, taking into account differences in purchasing
power (WHO, 2001). We capitalised on data published previously for an analysis of
screening alternatives in India (Goldie et al, 2005).
bVaccine cost is expressed as a
composite estimate of cost per vaccinated girl, and this total value is varied from I$5
to I$360 in sensitivity analysis; shown is the base case value. We assume the ‘cost per
vaccinated girl’ includes three doses, vaccine wastage, freight into the country,
supplies and administration, incremental programmatic costs for immunisation
services, and incremental costs of social mobilisation and outreach for a new pre-
adolescent vaccine (see Supplementary Appendix).
cScreening costs include staff
time, supplies, HPV DNA assay or Papanicolau test, and specimen transport.
Diagnostic and treatment costs include staff time, supplies, and equipment
depreciation; treatment includes cost of follow-up visits and complications. The cost
of the HPV DNA test (i.e., hybrid capture test) was based on a previous analysis
(Goldie et al, 2005). As this cost was intended to reflect an eventual negotiated price
for developing countries, we assumed the same cost for the rapid test and decreased
it by 50% in sensitivity analysis.
dModel parameters were varied ±75% in sensitivity
analysis.
eInvasive cancer costs include both direct medical and direct non-medical
costs. Direct medical costs of cancer care include staging of cancer severity,
hospitalisation, stage-appropriate treatment, and follow-up visits. Direct non-medical
costs and time costs associated with cancer care include all patient time in transport,
waiting, receiving treatment, and hospitalisation as well as actual transport costs.
fNon-medical costs include the time costs for two-way travel, waiting at the clinical
site, and receiving treatment, and the cost of transport for an average of two follow-
up visits. Screening and cryotherapy visits are carried out at a primary health clinic,
whereas all other visits occur at a district hospital (see Supplementary Appendix).
HPV, human papillomavirus.
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srequiring multiple visits became more attractive when loss to
follow-up was reduced.
We have previously reported how the comparative performance
of different cervical cancer prevention strategies depends on
several factors (Goldie et al, 2005, 2007; Garnett et al, 2006; Kim
et al, 2007a). For screening, as noted above, these include test
performance, cost, and loss to follow-up. For vaccination, these
include vaccine efficacy, coverage, and duration of protection.
Figure 3 shows how different assumptions about vaccination and
screening coverage will influence the level of cancer reduction
achievable with a strategy of pre-adolescent vaccination, assuming
100% efficacy, combined with screening three times per lifetime
using two-visit HPV DNA testing (shown by the bars). Similarly,
Figure 3 shows how vaccine efficacy and coverage will influence
the level of cancer reduction with a strategy of vaccination alone
(shown by the lines). A combined strategy of vaccination and
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Figure 2 Reduction in lifetime risk of cervical cancer. The mean reduction in lifetime risk of cervical cancer is shown with strategies using either vaccination
or screening (upper panel), and strategies combining both vaccination and screening (lower panel). The range represents the minimum and maximum
reductions achieved for each strategy across the good-fitting parameter sets.
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sscreening always provided greater cancer reduction than vaccina-
tion alone; however, the incremental benefits achieved by adding
screening three times per lifetime were greater at lower vaccination
coverage rates.
We can also obtain information about the coverage levels of
vaccination and screening required to achieve a specific threshold
reduction in cervical cancer from Figure 3. For example, without
screening, a threshold of 50% cancer reduction (dashed red line)
was expected to be attainable with vaccination alone only at
vaccination coverage rates exceeding 80% and vaccine efficacy of
100%. When screening and vaccination were combined, however,
several strategies would potentially achieve this threshold. At
vaccination coverage rates of 40–50%, screening coverage would
need to exceed 80%, but at vaccination coverage of 70%, screening
coverage of 40–50% would suffice. Assuming a cost per vaccinated
girl of I$10, the vast majority of these combination strategies had
cost-effectiveness ratios less than the per capita GDP when
compared to the next best strategy.
DISCUSSION
The vaccine-preventable cervical cancer burden in India is a product
of several factors, including the underlying cervical cancer incidence,
the proportion of cancer attributable to HPV 16 and 18, the long-
term vaccine efficacy, and the ability to achieve high coverage in
adolescent girls before sexual activity. Our results showed that with
70% coverage, the expected mean reduction in the lifetime risk of
cervical cancer with pre-adolescent vaccination alone was 44%.
The effectiveness of the vaccine could be lower than we projected
if older girls, who may have been infected previously with type 16 or
18, are vaccinated; if there is less robust vaccine-induced immunity
in girls with other diseases, such as severe anaemia, chronic illness
or HIV; or if vaccine-induced immunity wanes while individuals are
still at risk for new HPV infections. On the other hand, the impact of
the vaccine could be higher if there is long-term cross-protection
against non-16,18 type infection; if there are herd immunity benefits
to unvaccinated individuals; and if non-cervical HPV 16,18-related
cancers and diseases are prevented. For most of these factors, a lack
of data prohibit us from estimating the magnitude of individual
potential effects; that being said, these are uncertain issues for which
empiric data are needed.
We found that a combined approach of pre-adolescent
vaccination and screening three times per lifetime after age 30,
both at 70% coverage, provided a mean cancer reduction of
56–63%, depending on the specific screening strategy. Because the
mechanisms of effectiveness for vaccination and screening differ,
with vaccination preventing infections with HPV types 16 and 18,
and screening allowing for treatment of precancerous lesions
(caused by any high-risk HPV type) before progression to invasive
Table 2 Mean cancer reduction and impact of the cost per vaccinated girl on the incremental cost-effectiveness ratios (I$/YLS) of cervical cancer
prevention strategies
a
Cost per vaccinated girl
b
I$10 I$20 I$30 I$50 I$75 I$360
Mean cancer
Approximate implied per dose cost
Test reduction US$2 US$4 US$6 US$12 US$20 US$100
Table 2a. All strategies available
Natural history (no screening or vaccination) — — — — — —
Screening 1 time per lifetime at age 40 One-visit VIA 13% dom
c dom
c dom
c dom
c dom
c dom
c
Two-visit HPV DNA 16% dom
c dom
c dom
c dom
c dom
c dom
c
Screening two times per lifetime at One-visit VIA 21% dom
c dom
c dom
c dom
c dom
c dom
c
ages 35 and 40 Two-visit HPV DNA 24% dom
c dom
c dom
c dom
c dom
c dom
c
Three-visit cytology 21% dom
c dom
c dom
c dom
c dom
c dom
c
Screening three times per lifetime at One-visit VIA 29% dom
c I$60 I$60 I$60 I$60 I$60
ages 35, 40, and 45 Two-visit HPV DNA 33% dom
c dom
c dom
c dom
c dom
c dom
c
Vaccination 44% CS
d dom
c dom
c dom
c dom
c dom
c
Vaccination+screening one time per One-visit VIA 52% dom
c dom
c dom
c dom
c dom
c dom
c
lifetime at age 40 Two-visit HPV DNA 53% dom
c dom
c dom
c dom
c dom
c dom
c
Vaccination+screening two times per One-visit VIA 56% dom
c dom
c dom
c dom
c dom
c dom
c
lifetime at ages 35 and 40 Two-visit HPV DNA 57% dom
c dom
c dom
c dom
c dom
c dom
c
Three-visit cytology 56% dom
c dom
c dom
c dom
c dom
c dom
c
Vaccination+screening three times per One-visit VIA 61% I$290 I$340 I$630 I$1200 I$1920 I$7230
lifetime at ages 35, 40, and 45 Two-visit HPV DNA 63% I$82540 I$82540 I$82540 I$82540 I$82540 I$82540
Table 2b. Only two-visit HPV DNA testing available
Natural history — — — — — —
Screening alone three times per lifetime dom
c dom
c dom
c I$720 I$720 I$720
Vaccination CS
d I$190 I$390 I$890 dom
c dom
c
Vaccination+screening three times per lifetime I$1780 I$1780 I$1780 I$1780 I$2030 I$7650
aAfter eliminating strategies that are dominated, incremental cost-effectiveness ratios are calculated for the remaining strategies and are expressed in I$2005 per YLS. The
incremental cost-effectiveness ratios shown represent the mean costs divided by the mean effects of the good-fitting parameter sets.
bCost per vaccinated girl includes three
doses of vaccine, wastage, freight and supplies, administration, and immunisation support and programmatic costs.
cdom: these strategies are either more costly and less effective,
or less costly and less cost-effective, than alternative options, and are thus considered dominated.
dCS: cost saving. HPV: human papillomavirus. VIA: visual inspection with
acetic acid.
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scancer, they are synergistic, and provide substantially greater
benefits than either alone. Although screening three time per
lifetime prevents additional deaths from non-16 and 18-type
associated cancers, as well as 16,18-associated cancers in the
proportion of the population not vaccinated, it also provides some
insurance of cancer risk protection in the context of the
uncertainty around long-term vaccine performance in a non-
clinical trial situation. For example, across the good-fitting
parameter sets, the mean cancer reduction with vaccination alone
ranged from 28 to 57%, whereas with combined vaccination and
screening three times per lifetime using two-visit HPV DNA testing
ranged from 53 to 76%.
The cost-effectiveness of HPV vaccination will depend mostly on
the incremental programmatic costs associated with adding a pre-
adolescent vaccine to India’s vaccination programme, and also on
the ultimate negotiated vaccine price for India. We found that
provided the cost per vaccinated girl was I$10 or less (per dose cost
of approximately $2), vaccination alone was more effective and
cost-effective than screening alone. A combined approach of
pre-adolescent vaccination and screening three times per lifetime
(at ages 35, 40, and 45) using VIA cost I$290 per YLS; this ratio is a
fraction of India’s per capita GDP, and would be considered very
cost-effective according to suggested benchmarks for developing
countries (WHO, 2001). As the cost per vaccinated girl exceeded
I$10, vaccination alone was no longer more efficient than
screening alone. The incremental cost-effectiveness ratio for pre-
adolescent vaccination followed by screening in adulthood three
times per lifetime varied from I$340 per YLS at I$20 per vaccinated
girl, to I$1920 per YLS at I$75 per vaccinated girl. At a cost per
dose of approximately $100 (I$360 per vaccinated girl), vaccination
followed by screening exceeded I$7000 per YLS.
Although the rank-ordering of screening strategies from most
effective to least effective, was two-visit HPV DNA testing, single-
visit VIA, and three-visit cytology, differences between these
screening approaches were somewhat attenuated at higher
vaccination coverage rates. Vaccination plus screening three times
per lifetime with two-visit HPV DNA screening consistently
exceeded I$80000 per YLS due to a VIA strategy’s lower cost
and ability to deliver screening and treatment in a single visit.
However, with plausible changes in relative costs and test
performance, and the ability to obtain a same-day test result, the
use of HPV DNA testing was equally attractive. If a cytology-based
strategy could be conducted in two visits without the use of
colposcopy for diagnostic confirmation, it could be more attractive
than predicted by our analysis due to reduced loss to follow-up.
The results of this sensitivity analysis indicate that regions in India
should consider their own situations and infrastructure, and
identify which of these screening test options will be most feasible
for them. Most importantly, regardless of specific test choice, our
results provide strong support for screening adult women two to
three times per lifetime in addition to pre-adolescent vaccination.
Other influential assumptions on the cost-effectiveness ratio
include the values used for vaccine efficacy and the annual discount
rate. If vaccine efficacy is low, girls who are not protected still accrue
the costs of vaccination, thereby making it less cost-effective. Cost-
effectiveness analyses should be revisited as future data become
available on efficacy, necessity for and cost of boosters, and ability
to reach young girls who are not yet sexually active. Since the cancer
prevention benefits to vaccinated girls occur years after the costs are
paid, the effect of discounting both costs and benefits equally, as
recommended by guidelines for economic evaluations, (DCPP; Gold
et al, 1996; Drummond et al, 2005; WHO CHOICE) is substantial.
We acknowledge the complexity of the decision faced by countries
on whether to adopt the HPV vaccine, given the irrefutable reality
that women who will benefit from vaccination are not in the same
birth cohorts as the women who benefit from screening in the short-
run. Even so, as we have documented in other work, the benefits of
HPV 16,18 vaccination, when presented in formats that are not
influenced by discounting, are comparable to those of other new
vaccines. For example, we found that per 1000 girls vaccinated, 15
deaths would be averted (Goldie et al.2 0 0 8i np r e s s ) ,w h i c h
compares favourably to 3 deaths prevented per 1000 children
vaccinated for rotavirus (IAVI/PATH, 2007).
We recognise that because vaccination and screening are applied
to such different age groups, rely to different degrees on existing
infrastructure, and require the mobilisation of financial resources
that are likely to come from different ‘pots’, the feasibility of
achieving wide coverage with screening vs vaccination could vary
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Figure 3 Impact of vaccination coverage, screening coverage, and vaccine efficacy on clinical benefits. This figure depicts how cancer reduction is
influenced by different levels of vaccination and screening coverage with a combined strategy of vaccination plus screening three times per lifetime using two-
visit HPV DNA testing. Cancer reduction is on the y axis, and vaccination coverage on the x axis. The coloured bars represent different coverage levels for
screening (pale yellow, 20%; gold, 40%; green, 60%; orange, 80%; blue, 100%). The lines represent a strategy of vaccination alone at different levels of vaccine
efficacy (white, 70%; light grey, 80%; dark grey, 90%; black, 100%). The dashed red line represents a threshold of 50% cancer reduction.
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sgreatly within India, providing a challenge in designing a national
prevention programme. It is possible that in regions where
screening is not likely to be feasible, focused efforts to achieve high
coverage rates for pre-adolescent vaccination would be the most
worthwhile investment. In contrast, in regions where screening is
successfully being conducted within demonstration projects or
clinical studies, it may be most cost-effective to continue to expand
those efforts and combine them with pre-adolescent vaccination – at
vaccination coverage rates of even 50%, a combined approach could
substantially reduce the incidence of cancer.
In India, where out-of-pocket costs of health care can topple a
household into extreme poverty, if the opportunity for vaccination is
restricted to those willing to pay higher costs in the private sector,
most women will not benefit. From a population perspective, since
80% of Indian women live on less than I$2 per day (World Bank),
even at a drastically reduced price, the vast majority could not afford
this vaccine and provision by the public health sector will be
necessary. Although a cost-effectiveness analysis provides informa-
tion on value for money to a decision maker with a long-term
perspective on investing in health, it is not equivalent to providing
information on affordability to the payer for whom the short-term
perspective is more relevant. Both the financial costs (i.e.,
affordability) and the cost-effectiveness profile (i.e., value for money)
of an HPV vaccine will need to be favourable as this vaccine will
compete for dollars earmarked for existing immunisation programs.
Our analysis has several limitations, and thus, we emphasise that
our results are intended to provide quantitative approximations of
the potential benefits of HPV vaccination, and to provide
qualitative insight into the relative value of primary and secondary
prevention. We have previously discussed the limitations inherent
in our modelling approach (Goldhaber-Fiebert et al, 2007; Goldie
et al, 2007; Kim et al, 2007a), but we briefly mention key points
here. In addition to model parameter uncertainty, there are
uncertainties with respect to the natural history of HPV, especially
in older women, the nature of type-specific immunity following
natural infection, and the relationships between different HPV
types in the case of multiple infections. Similarly, a lack of high
quality data on temporal trends of HPV-related disease limited our
ability to calibrate the model to different time points, and
contributed to the choice to simulate a single birth cohort.
We made a tradeoff in choosing to use our individual-based
microsimulation model for this analysis and not our HPV 16 and
18 transmission model (Kim et al, 2007b). This was a purposeful
decision as the former can simulate detailed screening strategies as
well as vaccination, and includes other HPV types not targeted by
the vaccine, enabling us to take advantage of all available data by
calibrating to many epidemiological targets (Garnett et al, 2006).
As the model includes vaccine-targeted and non-targeted HPV
types, we were able to explore the potential effect of an increase in
non-vaccine-targeted HPV types. We have previously documented
a small expected increase in non-16,18 cancers (Goldie et al, 2003,
2007), although we again found that the impact on the main cost-
effectiveness results was small. While our independent dynamic
model (Kim et al, 2007b) has been previously used to include the
herd immunity effects in an HPV vaccine policy analysis,
sensitivity analyses that reduced incidence based on these findings,
found the main policy results would be unlikely to change. Data on
type-specific transmission by age and sex will be useful to include
in future analyses once available.
Given the range of uncertainties and the limitations of this
analysis, our findings should be considered exploratory and our
estimates of cost-effectiveness approximate, and should be
interpreted in the context of the analytic purpose of this work,
that is, to leverage the best available data to provide insight into
decisions that policy makers in India are discussing right now. A
country as large and as heterogeneous as India will need to
conduct its own financial analyses, assess the effectiveness and
feasibility of alternative modes of delivery, and identify potential
economies of scale with other programmes that might target
adolescents. The strategies that we have identified as cost-effective
in this analysis may still be prohibitively expensive in India, and
information on affordability, potential financing mechanisms, and
likelihood of uptake and acceptability will need to be considered
by decision makers as well.
Prevention and treatment of cervical cancer, the leading cause of
cancer in Indian women, is a priority according to the country’s
National Cancer Control Programme (Government of India, 2005).
On the basis of age-specific incidence and projected demographic
changes, the expected new cases of cervical cancer in India will
increase from 132082 in year 2002, to more than 330000 in 2050
(Ferlay et al, 2004). The vast majority of women will lack curative
treatment, and thus, approximately two-thirds will die from this
preventable disease. The implications for these women’s families
and communities are profound, as this cancer affects women at an
age when they are vital to social and economic stability. The
opportunity to prevent these deaths is now inarguable with the
availability of a vaccine to prevent HPV 16,18 infection, new
diagnostics for HPV DNA testing, and promising secondary
prevention strategies that target women after age 30 and perform
screening and treatment in as few visits as possible (Goldie et al,
2005). If the cost per vaccinated girl is less than I$10, implying a
per dose cost of approximately $2, vaccination is likely to be
extremely cost-effective in India. The most effective strategy,
within a framework that would still be potentially cost-effective in
India, would be pre-adolescent vaccination, followed by screening
three times per lifetime between ages 35 and 45; assuming a
vaccination coverage rate of 70%, this strategy would be expected
to prevent more than 1.25 million cervical cancer deaths over the
lifetimes of 10 consecutive birth cohorts.
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